GX 188E

Drug Profile

GX 188E

Alternative Names: GX-188; GX188E; Papitrol; pGX27-E6E7

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 07 Mar 2018 Genexine plans a phase I/II trial in Cervical cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in South Korea (IM) (NCT03444376)
  • 20 Feb 2018 Genexine in-licenses PharmaJet Stratis® and Tropis® devices from PharmaJet
  • 19 Jun 2017 Genexine plans a phase III trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top